Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"

Sci Transl Med. 2019 Jul 17;11(501):eaau0416. doi: 10.1126/scitranslmed.aau0416.

¹ University of Maryland School of Medicine, Baltimore, MD 21201, USA. dperrotti@som.umaryland.edu.
² Department of Haematology, Imperial College London, London W12 0HS, UK.
³ Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
⁴ University of Chester Medical School, Chester CH2 1BR, UK.
⁵ Department of Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
⁶ Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA.
⁷ University of Navarra, Pamplona 31009, Spain.
⁸ Department of Leukemia, MD Anderson Cancer Center, Houston, 77054 TX, USA.
⁹ School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia.

Abstract

LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis.